The XIENCE V everolimus-eluting stent significantly reduced major adverse cardiac events compared to the TAXUS paclitaxel-eluting stent in women (8.5% vs 16.4%) and men (6.7% vs 10.9%) at two years.
Meta-Analysis (n=1,301)
Randomized
Does everolimus-eluting stent reduce major adverse cardiac events and angiographic late loss compared to paclitaxel-eluting stent in male and female patients with coronary artery disease?
Everolimus-eluting stents significantly reduce major adverse cardiac events and angiographic late loss compared to paclitaxel-eluting stents at two years in both men and women with coronary artery disease.
Absolute Event Rate: 8.5% vs 16.4%
p-value: p=0.02
AIMS: To assess the safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the TAXUS paclitaxel-eluting stent (PES) in women at two years. METHODS AND RESULTS: In this pooled analysis, a cohort of 395 women and 906 men was studied by using patient level and lesion level clinical data from SPIRIT II and SPIRIT III studies. Women enrolled in these two studies had higher demographic and lesion risk characteristics than their male counterparts. In-stent and in-segment late loss (LL) was significantly less in the women in the EES group compared to the women in the PES group (in-stent 0.15+/-0.44 mm vs. 0.45+/-0.51 mm; P<0.01, in-segment 0.09+/-0.46 mm vs. 0.29+/-0.40 mm; P<0.01). In women, EES compared to PES resulted in significant reductions in major adverse cardiac events (MACE) (8.5% vs 16.4%; p=0.02) and in target vessel failure (TVF) (11.2% vs 19.5%; p=0.02) at two years. In men, a significant difference was seen in in-stent LL and in-stent % diameter stenosis (DS) favouring EES (in-stent LL 0.14+/-0.33 mm vs. 0.28+/-0.47 mm; P<0.01, in-stent %DS 9.28+/-13.86 vs. 13.64+/-18.31; P<0.01). MACE rates at two years were lower in males treated with EES compared to PES (6.7% vs. 10.9%; p=0.03). The interaction between gender and stent type was not found to be significant for MACE at two years. CONCLUSIONS: In this pooled analysis of two randomised trials, at two years, EES compared to PES resulted in reduced angiographic LL, fewer MACE and TVF events in women and reduced angiographic LL and %DS and fewer MACE events in men.
Seth et al. (Mon,) conducted a meta-analysis in coronary artery disease (n=1,301). XIENCE V everolimus-eluting stent (EES) vs. TAXUS paclitaxel-eluting stent (PES) was evaluated on major adverse cardiac events (MACE) in women (p=0.02). The XIENCE V everolimus-eluting stent significantly reduced major adverse cardiac events compared to the TAXUS paclitaxel-eluting stent in women (8.5% vs 16.4%) and men (6.7% vs 10.9%) at two years.